International Association for the Study of Lung Cancer (IASLC) posted on LinkedIn:
“FDA Accelerated Approval Alert
The FDA has granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis) for adults with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) showing high c-Met protein expression—after prior systemic treatment.
Based on the LUMINOSITY trial
• 35% overall response rate.
• Median duration of response: 7.2 months.
Why this matters for lung cancer care:
• Offers a new option for patients with high c-Met protein expression.
• Fills a treatment gap for previously treated NSCLC patients.
• Highlights the impact of biomarker-driven therapies.
More posts featuring NSCLC.